OYST News and Press, Oyster Point Pharma Inc. From 08/17/22

PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class phar...

PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class phar...

Oyster Point Pharma, Inc. (OYST) Q2 2022 Results Conference Call August 11, 2022 04:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chi...

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q2 2022 Earnings Call Transcript...

TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2 ’ 22 Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals ...

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-clas...

TYRVAYA Now Covered by Commercial Prescription Drug Plans Managed by the Nation’s Top Three Pharmacy Benefit Manager (PBM) Group Purchasing Organizations (GPOs) Expanding Patient Access Programs to Include More Eligible Patients with Dry Eye Disease Launch t...

Oyster Point Pharma ( NASDAQ: OYST ) is trading ~11% higher after H.C. Wainwright initiated coverage with a Buy rating and a price target of $20. H.C. Wainwright analyst Matthew Caufield said the company has a "differentiated" dry eye nasal spray approval compleme...

OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line. Here, they have abysmally failed to make any money. Oyster Point Pharma, Inc. (OYST) has an approved p...

Oyster Point Pharma (NASDAQ:OYST) will implement a cost-savings plan that it says will lead to $6M-$8M in savings this year but also includes laying off up to 50 workers. The ophthalmic diseases focused biotech said it expects savings of $40M-$48M in 2023. Oyster Point said that the move will...